EGFR and non-small cell lung carcinoma: Immunotherapy with programmed cell death‐1 (PD‐1) or programmed cell death ligand‐1 (PD‐L1) monoclonal antibodies has displayed glorious clinical benefit for wild‐type (WT) advanced NSCLC, but the efficacy of PD‐1/PD‐L1 inhibitor was much limited for patients with oncogenic drivers including EGFR mutations or ALK fusions.18, 19